Jindawei group plans to invest in antineoplastic new drug of Guoding Biotechnology

This investment is subject to the approval of the competent authorities on both sides of the Straits After the completion of the transaction, jindawei will hold no more than 5.17% of Guoding biotechnology Recently, Guoding announced that the anti lung cancer Ras target new drug androjian has been approved by the US FDA and will enter the second phase of clinical trials Liu Shengyong, chairman of the board of directors, said that since the drug meets the conditions of breakthrough therapy and indications without medicine, he will strive to complete the second phase of clinical trials, and directly send it to FDA to apply for drug certificate, and strive to be listed in 2017 In order to start multi center clinical trials in many countries, Guoding has recently signed a contract with the world-famous cro company icon Androjian expects that the second phase of clinical trials to be started next year will be implemented by icon, and it is estimated that 60 cases will be closed The clinical duration is two and a half years, with an investment of about 10 million US dollars In addition, Guoding expects to apply for colorectal cancer, pancreatic cancer, lupus erythematosus, fatty liver and other new indications after the completion of clinical two years of lung cancer Liu Shengyong pointed out that the number of people dying of lung cancer in the world is up to 1.4 million every year, and Taiwan is one of the three major causes of death About 85% of lung cancer patients in the world are non-small cell lung cancer Due to the lack of effective treatment for lung cancer, the 5-year survival rate at the end of the period is almost zero According to statistics, 30% of cancer patients have ras gene mutation, and the mutation rate in lung cancer, colorectal cancer and pancreatic cancer is still higher than the average level At present, there is no drug that can inhibit ras gene Chen Zhiming, chief researcher of Guoding R & D department, pointed out that androjian had passed the first phase of FDA clinical trial in the United States The first phase is mainly safety test and pharmacokinetic test According to the observation of clinical trials, vomiting and diarrhea can be relieved after 4 weeks of administration; in terms of effectiveness, more than 60% of tumors can be controlled after 3 months of continuous administration, of which 25% tumors are shrunk In addition, in recent two years, 11 new drugs have obtained new drug certificates directly after the end of the second phase of FDA in the United States The fastest time from clinical to obtaining drug certificates is only 18 months Liu Shengyong believes that as androjian is a new compound and lung cancer, pancreatic cancer and other diseases are incurable, it will follow the rapid review mode to directly apply for drug evidence If it is successful, the new drug will have the opportunity to go on the market in 2017 Guoding biotechnology was founded in 2002 with a capital of about 700 million yuan The largest shareholder is yuanxiong group It is expected that the shareholding ratio will be about 18-19% after the completion of capital increase at the end of the year In addition, the total shareholding ratio of Dapeng, Yipeng and shuangpeng investment led by new chairman Xie Nanqiang will also be about 10% Jindawei Group Co., Ltd is a key high-tech enterprise of the national torch plan and one of the first batch of new certified high-tech enterprises in Xiamen The company aims to improve the quality of human health life, and is committed to the innovation and development of nutrition enhancers and biomedical fields.